期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.666137
关键词
gene signature (GS); breast cancer; immune infiltration; immunotherapy; prognosis; chemotherapy
类别
资金
- National Natural Science Foundation of China (NSFC) [81272265, 81472658]
- China Scholarship Council (CSC) [201908500101, 202008080024]
The study established a gene signature to predict patient prognosis and treatment responses based on the relationship between immune cells and breast cancer progression. A higher immune infiltration-related risk score indicated a worse prognosis and less sensitivity to immunotherapy. A new nomogram combining gene signature and clinicopathological features was created to improve risk stratification and risk assessment for individual patients.
Breast cancer patients show significant heterogeneity in overall survival. Current assessment models are insufficient to accurately predict patient prognosis, and models for predicting treatment response are lacking. We evaluated the relationship between various immune cells and breast cancer and confirmed the association between immune infiltration and breast cancer progression. Different bioinformatics and statistical approaches were combined to construct a robust immune infiltration-related gene signature for predicting patient prognosis and responses to immunotherapy and chemotherapy. Our research found that a higher immune infiltration-related risk score (IRS) indicates that the patient has a worse prognosis and is not very sensitive to immunotherapy. In addition, a new nomogram was constructed based on the gene signature and clinicopathological features to improve the risk stratification and quantify the risk assessment of individual patients. Our study might contribute to the optimization of the risk stratification for survival and the personalized management of breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据